145 related articles for article (PubMed ID: 25426551)
1. Human recombinant truncated RNASET2, devoid of RNase activity; A potential cancer therapeutic agent.
Nesiel-Nuttman L; Schwartz B; Shoseyov O
Oncotarget; 2014 Nov; 5(22):11464-78. PubMed ID: 25426551
[TBL] [Abstract][Full Text] [Related]
2. A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization.
Smirnoff P; Roiz L; Angelkovitch B; Schwartz B; Shoseyov O
Cancer; 2006 Dec; 107(12):2760-9. PubMed ID: 17109444
[TBL] [Abstract][Full Text] [Related]
3. ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics.
Roiz L; Smirnoff P; Bar-Eli M; Schwartz B; Shoseyov O
Cancer; 2006 May; 106(10):2295-308. PubMed ID: 16586499
[TBL] [Abstract][Full Text] [Related]
4. Human RNASET2 derivatives as potential anti-angiogenic agents: actin binding sequence identification and characterization.
Nesiel-Nuttman L; Doron S; Schwartz B; Shoseyov O
Oncoscience; 2015; 2(1):31-43. PubMed ID: 25815360
[TBL] [Abstract][Full Text] [Related]
5. The 1.8 Å crystal structure of ACTIBIND suggests a mode of action for T2 ribonucleases as antitumorigenic agents.
de Leeuw M; González A; Lanir A; Roiz L; Smirnoff P; Schwartz B; Shoseyov O; Almog O
J Med Chem; 2012 Feb; 55(3):1013-20. PubMed ID: 22216760
[TBL] [Abstract][Full Text] [Related]
6. [Angiogenin and its role in angiogenesis].
Shestenko OP; Nikonov SD; Mertvetsov NP
Mol Biol (Mosk); 2001; 35(3):349-71. PubMed ID: 11443914
[TBL] [Abstract][Full Text] [Related]
7. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the baculovirus-insect cell and Pichia pastoris heterologous systems for the expression of the human tumor suppressor protein RNASET2.
Campomenosi P; Cinquetti R; Tallarita E; Lindqvist C; Raimondi I; Grassi P; Näsman J; Dell A; Haslam SM; Taramelli R; Acquati F
Biotechnol Appl Biochem; 2011; 58(1):39-49. PubMed ID: 21446958
[TBL] [Abstract][Full Text] [Related]
9. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
10. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
11. Characterization of RNASET2, the first human member of the Rh/T2/S family of glycoproteins.
Campomenosi P; Salis S; Lindqvist C; Mariani D; Nordström T; Acquati F; Taramelli R
Arch Biochem Biophys; 2006 May; 449(1-2):17-26. PubMed ID: 16620762
[TBL] [Abstract][Full Text] [Related]
12. Development of antiangiogenin peptide using a phage-displayed peptide library.
Gho YS; Lee JE; Oh KS; Bae DG; Chae CB
Cancer Res; 1997 Sep; 57(17):3733-40. PubMed ID: 9288781
[TBL] [Abstract][Full Text] [Related]
13. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity.
Moroianu J; Riordan JF
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1677-81. PubMed ID: 8127865
[TBL] [Abstract][Full Text] [Related]
14. Pleiotropic modes of action in tumor cells of RNASET2, an evolutionary highly conserved extracellular RNase.
Lualdi M; Pedrini E; Rea K; Monti L; Scaldaferri D; Gariboldi M; Camporeale A; Ghia P; Monti E; Tomassetti A; Acquati F; Taramelli R
Oncotarget; 2015 Apr; 6(10):7851-65. PubMed ID: 25797262
[TBL] [Abstract][Full Text] [Related]
15. Copper binding to naturally occurring, lactam form of angiogenin differs from that to recombinant protein, affecting their activity.
La Mendola D; Arnesano F; Hansson Ö; Giacomelli C; Calò V; Mangini V; Magrì A; Bellia F; Trincavelli ML; Martini C; Natile G; Rizzarelli E
Metallomics; 2016 Jan; 8(1):118-24. PubMed ID: 26594037
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
18. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
19. Tumor and metastasis suppression by the human RNASET2 gene.
Acquati F; Possati L; Ferrante L; Campomenosi P; Talevi S; Bardelli S; Margiotta C; Russo A; Bortoletto E; Rocchetti R; Calza R; Cinquetti R; Monti L; Salis S; Barbanti-Brodano G; Taramelli R
Int J Oncol; 2005 May; 26(5):1159-68. PubMed ID: 15809705
[TBL] [Abstract][Full Text] [Related]
20. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
